Gene · 8717
TRADD: TNFRSF1A associated via death domain
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TRADD: TNFRSF1A associated via death domain. Genes, record 8717. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8717
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q15628 | Tumor necrosis factor receptor type 1-associated DEATH domain protein | 312 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents46
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 6631 | Q15628 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 16517 | Q15628 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 6631 | Q15628 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 16517 | Q15628 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 16517 | Q15628 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 8726 | Q15628 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 16356 | Q15628 | Espacenet |
| US 11708396 B2 | 2023-07-25 | 2030 | Q15628 | Espacenet |
| US 11701379 B2 | 2023-07-18 | 204 | Q15628 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 89125 | Q15628 | Espacenet |
1 to 10 of 46
See all 46 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,604
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TRADD papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 20 | 2025 |
| ZIASC010376 | TNF Signaling, Cell Death and Cancer | 9 | 2025 |
| ZIABC010783 | Inflammation, Macrophage Differentiation, and Cancer | 5 | 2025 |
| P01CA019014 | Viral Oncogenesis, Latency, and Replication | 4 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 4 | 2025 |
| P30CA047904 | Cancer Center Support Grant | 4 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 4 | 2025 |
| ZIABC010440 | Protein Structure, Stability, and Amyloid Formation | 4 | 2025 |
| ZIABC010441 | Biomolecular Recognition and Binding Mechanisms | 4 | 2025 |
| ZIDAR041180 | Clinical Support Services for the NIAMS Intramural Research Program | 4 | 2025 |
1 to 10 of 1,604Source NIH's project files
See all 1,604 nih grantsPapers2,847
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Jaceidin Inhibits Proliferation and Promotes Apoptosis in Oral Squamous Cell Carcinoma Cells by Regulating Survivin and AKT/ERK Signaling Pathways. | Int J Mol Sci | 2026 | 42737771 | PubTator, text mining | PubMed |
| Structural characterization of PAMK and its protective effect against thymic necroptosis in goslings. | Vet Q | 2026 | 42677992 | PubTator, text mining | PubMed |
| Deciphering HPV-Associated Immune Evasion in Cervical Cancer Through Multi-Omics Profiling and Computational Screening. | Anal Cell Pathol (Amst) | 2026 | 42635083 | PubTator, text mining | PubMed |
| Binding of death receptor 3 (DR3) to intracellular TRADD and TRAF2 is independent of its natural ligand, TL1A. | J Immunol | 2026 | 42522260 | PubTator, text mining | PubMed |
| Diosgenin inhibits necroptosis to alleviate NAFLD by blocking the RIPK1/RIPK3/MLKL pathway. | J Nutr Biochem | 2026 | 42323101 | PubTator, text mining | PubMed |
| Functional variants in ATF4 and PMAIP1 reveal mitochondrial apoptosis dependencies driving pancreatic cancer progression. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42024236 | PubTator, text mining | PubMed |
| Deciphering the Chemotherapeutic Mechanism of Ferulic Acid: Insight Into the Role Against Multiple Human Cancers. | Cancer Innov | 2026 | 42016510 | PubTator, text mining | PubMed |
| Gene Expression Alterations Associated With Resveratrol-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Osteosarcoma Cancer Cells. | J Cell Mol Med | 2026 | 41937498 | PubTator, text mining | PubMed |
| Role of aging‑related cytokines in neurodegenerative disease (Review). | Int J Mol Med | 2026 | 41930561 | PubTator, text mining | PubMed |
| Electric dipole moment drives the dynamics of the TNFR1 complex I signalosome. | Nature | 2026 | 41922760 | Swiss-Prot, curated | PubMed |
1 to 10 of 2,847
See all 2,847 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8717
GET https://conductscience.org/api/genes/v1/8717/patents?page=2